- Home
- All Stock List
- BSE
- Zim Laboratories Ltd Share Price
91.24
0.56 (0.62%)
-
Underperforms Index
-4.15%
Return (1Y)
Underperformed BSE Sensex by 11.97%
-
More Volatile
2.86%
Standard Deviation (1Y)
Higher than BSE Sensex by 1.92%
-
Not so consistent
6/12
Months
underperformed BSE Sensex
-
AxisDirect View
No View
131
80
News & Announcements
-
Zim Laboratories (ZIM) has entered into a Dossier License, Product Supply, and Technology Know-How License Agreement with Globalpharma Co. (L.L.C.), a leading UAE-based pharmaceutical manufacturer and a wholly owned subsidiary of Dubai Investments, one of the region's premier investment entities.
This partnership encompasses dossier licensing, bulk product supply, and the licensing of ZIM Labs' proprietary Oral Thin Film technology platform, ThinOral?. Under the agreement, Globalpharma will register and commercialize 10 OTF-based Pharmaceutical and Nutraceutical products developed by ZIM, catering to regional patient needs with advanced, user-friendly dosage forms.
Initially, ZIM Labs will supply bulk products while providing complete regulatory support for market registration in the UAE. Post-approval, ZIM will deliver ready-to-use powder mixes, enabling Globalpharma to undertake localized manufacturing and marketing of the finished formulations.
Powered by Capital Market - Live News
-
Zim Labs gets regulatory nod in Portugal for multiple sclerosis treatment drug Dimethyl Fumarate
33 days ago
Zim Labs gets regulatory nod in Portugal for multiple sclerosis treatment drug Dimethyl Fumarate
20 - Mar - 2025 12:00 | 33 days ago
This authorization from INFARMED, which is the Portuguese National Authority of Medicines and Health Products, will facilitate faster approvals in other European Union countries as well as the UK and other markets globally resulting in better commercialisation opportunities, the company stated.
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS) and are developed using ZIM?s proprietary technology and is bioequivalent to the Innovator?s product.
According to IQVIA, the EU market size for this product in 2023 was approximately $800 million while UK contributed $200 million. Other markets (Ex USA & Japan) contributed $42 million.
ZIM Laboratories Limited (the Company) is a research-driven Pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments.
The company's consolidated net profit declined 16.32% to Rs 4 crore as revenue remained flat at Rs 96.33 crore in in the quarter ended December 2024 as compared with the previous quarter ended December 2023.
The scrip rose 0.27% currently trade at to Rs 85 on the BSE.
Powered by Capital Market - Live News
-
Zim Laboratories consolidated net profit declines 16.32% in the December 2024 quarter
11 - Feb - 2025 12:00 | 70 days ago
Net profit of Zim Laboratories declined 16.32% to Rs 4.00 crore in the quarter ended December 2024 as against Rs 4.78 crore during the previous quarter ended December 2023. Sales rose 0.04% to Rs 96.33 crore in the quarter ended December 2024 as against Rs 96.29 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 96.33 96.29 0 OPM % 12.01 11.98 - PBDT 10.58 10.95 -3 PBT 5.70 7.01 -19 NP 4.00 4.78 -16 Powered by Capital Market - Live News
-
Zim Labs gets regulatory nod in Portugal for multiple sclerosis treatment drug Dimethyl Fumarate
33 days ago
Zim Labs gets regulatory nod in Portugal for multiple sclerosis treatment drug Dimethyl Fumarate
20 - Mar - 2025 12:00 | 33 days ago
This authorization from INFARMED, which is the Portuguese National Authority of Medicines and Health Products, will facilitate faster approvals in other European Union countries as well as the UK and other markets globally resulting in better commercialisation opportunities, the company stated.
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS) and are developed using ZIM?s proprietary technology and is bioequivalent to the Innovator?s product.
According to IQVIA, the EU market size for this product in 2023 was approximately $800 million while UK contributed $200 million. Other markets (Ex USA & Japan) contributed $42 million.
ZIM Laboratories Limited (the Company) is a research-driven Pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments.
The company's consolidated net profit declined 16.32% to Rs 4 crore as revenue remained flat at Rs 96.33 crore in in the quarter ended December 2024 as compared with the previous quarter ended December 2023.
The scrip rose 0.27% currently trade at to Rs 85 on the BSE.
Powered by Capital Market - Live News
-
Zim Laboratories consolidated net profit declines 16.32% in the December 2024 quarter
11 - Feb - 2025 12:00 | 70 days ago
Net profit of Zim Laboratories declined 16.32% to Rs 4.00 crore in the quarter ended December 2024 as against Rs 4.78 crore during the previous quarter ended December 2023. Sales rose 0.04% to Rs 96.33 crore in the quarter ended December 2024 as against Rs 96.29 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 96.33 96.29 0 OPM % 12.01 11.98 - PBDT 10.58 10.95 -3 PBT 5.70 7.01 -19 NP 4.00 4.78 -16 Powered by Capital Market - Live News
-
Zim Laboratories to declare Quarterly Results
77 days ago
-
Zim Laboratories (ZIM) has entered into a Dossier License, Product Supply, and Technology Know-How License Agreement with Globalpharma Co. (L.L.C.), a leading UAE-based pharmaceutical manufacturer and a wholly owned subsidiary of Dubai Investments, one of the region's premier investment entities.
This partnership encompasses dossier licensing, bulk product supply, and the licensing of ZIM Labs' proprietary Oral Thin Film technology platform, ThinOral?. Under the agreement, Globalpharma will register and commercialize 10 OTF-based Pharmaceutical and Nutraceutical products developed by ZIM, catering to regional patient needs with advanced, user-friendly dosage forms.
Initially, ZIM Labs will supply bulk products while providing complete regulatory support for market registration in the UAE. Post-approval, ZIM will deliver ready-to-use powder mixes, enabling Globalpharma to undertake localized manufacturing and marketing of the finished formulations.
Powered by Capital Market - Live News
-
Zim Labs gets regulatory nod in Portugal for multiple sclerosis treatment drug Dimethyl Fumarate
33 days ago
Zim Labs gets regulatory nod in Portugal for multiple sclerosis treatment drug Dimethyl Fumarate
20 - Mar - 2025 12:00 | 33 days ago
This authorization from INFARMED, which is the Portuguese National Authority of Medicines and Health Products, will facilitate faster approvals in other European Union countries as well as the UK and other markets globally resulting in better commercialisation opportunities, the company stated.
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS) and are developed using ZIM?s proprietary technology and is bioequivalent to the Innovator?s product.
According to IQVIA, the EU market size for this product in 2023 was approximately $800 million while UK contributed $200 million. Other markets (Ex USA & Japan) contributed $42 million.
ZIM Laboratories Limited (the Company) is a research-driven Pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments.
The company's consolidated net profit declined 16.32% to Rs 4 crore as revenue remained flat at Rs 96.33 crore in in the quarter ended December 2024 as compared with the previous quarter ended December 2023.
The scrip rose 0.27% currently trade at to Rs 85 on the BSE.
Powered by Capital Market - Live News
-
Zim Laboratories consolidated net profit declines 16.32% in the December 2024 quarter
11 - Feb - 2025 12:00 | 70 days ago
Net profit of Zim Laboratories declined 16.32% to Rs 4.00 crore in the quarter ended December 2024 as against Rs 4.78 crore during the previous quarter ended December 2023. Sales rose 0.04% to Rs 96.33 crore in the quarter ended December 2024 as against Rs 96.29 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 96.33 96.29 0 OPM % 12.01 11.98 - PBDT 10.58 10.95 -3 PBT 5.70 7.01 -19 NP 4.00 4.78 -16 Powered by Capital Market - Live News
-
Zim Laboratories to declare Quarterly Results
77 days ago
-
Zim Laboratories (ZIM) has entered into a Dossier License, Product Supply, and Technology Know-How License Agreement with Globalpharma Co. (L.L.C.), a leading UAE-based pharmaceutical manufacturer and a wholly owned subsidiary of Dubai Investments, one of the region's premier investment entities.
This partnership encompasses dossier licensing, bulk product supply, and the licensing of ZIM Labs' proprietary Oral Thin Film technology platform, ThinOral?. Under the agreement, Globalpharma will register and commercialize 10 OTF-based Pharmaceutical and Nutraceutical products developed by ZIM, catering to regional patient needs with advanced, user-friendly dosage forms.
Initially, ZIM Labs will supply bulk products while providing complete regulatory support for market registration in the UAE. Post-approval, ZIM will deliver ready-to-use powder mixes, enabling Globalpharma to undertake localized manufacturing and marketing of the finished formulations.
Powered by Capital Market - Live News
-
Zim Labs gets regulatory nod in Portugal for multiple sclerosis treatment drug Dimethyl Fumarate
33 days ago
Zim Labs gets regulatory nod in Portugal for multiple sclerosis treatment drug Dimethyl Fumarate
20 - Mar - 2025 12:00 | 33 days ago
This authorization from INFARMED, which is the Portuguese National Authority of Medicines and Health Products, will facilitate faster approvals in other European Union countries as well as the UK and other markets globally resulting in better commercialisation opportunities, the company stated.
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS) and are developed using ZIM?s proprietary technology and is bioequivalent to the Innovator?s product.
According to IQVIA, the EU market size for this product in 2023 was approximately $800 million while UK contributed $200 million. Other markets (Ex USA & Japan) contributed $42 million.
ZIM Laboratories Limited (the Company) is a research-driven Pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments.
The company's consolidated net profit declined 16.32% to Rs 4 crore as revenue remained flat at Rs 96.33 crore in in the quarter ended December 2024 as compared with the previous quarter ended December 2023.
The scrip rose 0.27% currently trade at to Rs 85 on the BSE.
Powered by Capital Market - Live News
-
Zim Laboratories consolidated net profit declines 16.32% in the December 2024 quarter
11 - Feb - 2025 12:00 | 70 days ago
Net profit of Zim Laboratories declined 16.32% to Rs 4.00 crore in the quarter ended December 2024 as against Rs 4.78 crore during the previous quarter ended December 2023. Sales rose 0.04% to Rs 96.33 crore in the quarter ended December 2024 as against Rs 96.29 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 96.33 96.29 0 OPM % 12.01 11.98 - PBDT 10.58 10.95 -3 PBT 5.70 7.01 -19 NP 4.00 4.78 -16 Powered by Capital Market - Live News
-
Zim Labs gets regulatory nod in Portugal for multiple sclerosis treatment drug Dimethyl Fumarate
33 days ago
Zim Labs gets regulatory nod in Portugal for multiple sclerosis treatment drug Dimethyl Fumarate
20 - Mar - 2025 12:00 | 33 days ago
This authorization from INFARMED, which is the Portuguese National Authority of Medicines and Health Products, will facilitate faster approvals in other European Union countries as well as the UK and other markets globally resulting in better commercialisation opportunities, the company stated.
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS) and are developed using ZIM?s proprietary technology and is bioequivalent to the Innovator?s product.
According to IQVIA, the EU market size for this product in 2023 was approximately $800 million while UK contributed $200 million. Other markets (Ex USA & Japan) contributed $42 million.
ZIM Laboratories Limited (the Company) is a research-driven Pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments.
The company's consolidated net profit declined 16.32% to Rs 4 crore as revenue remained flat at Rs 96.33 crore in in the quarter ended December 2024 as compared with the previous quarter ended December 2023.
The scrip rose 0.27% currently trade at to Rs 85 on the BSE.
Powered by Capital Market - Live News
-
Zim Laboratories consolidated net profit declines 16.32% in the December 2024 quarter
11 - Feb - 2025 12:00 | 70 days ago
Net profit of Zim Laboratories declined 16.32% to Rs 4.00 crore in the quarter ended December 2024 as against Rs 4.78 crore during the previous quarter ended December 2023. Sales rose 0.04% to Rs 96.33 crore in the quarter ended December 2024 as against Rs 96.29 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 96.33 96.29 0 OPM % 12.01 11.98 - PBDT 10.58 10.95 -3 PBT 5.70 7.01 -19 NP 4.00 4.78 -16 Powered by Capital Market - Live News
-
Zim Laboratories to declare Quarterly Results
77 days ago
Stock Trivia
FII shareholding in Zim Laboratories Ltd has decreased by -95.06% since past 3 Months
FII shareholding in Zim Laboratories Ltd has increased by 85.96% since past 1 Year
FII shareholding in Zim Laboratories Ltd has decreased by -95.06% since past 3 Months
FII shareholding in Zim Laboratories Ltd has increased by 85.96% since past 1 Year
FII shareholding in Zim Laboratories Ltd has decreased by -95.06% since past 3 Months
FII shareholding in Zim Laboratories Ltd has increased by 85.96% since past 1 Year
